Evidence map›Paper›PMID 37272757›Full record

ArticleCancer research2023

The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer.

Zheqi Li, Tianqin Li, Megan E Yates, Yang Wu, Amanda Ferber, Lyuqin Chen, Daniel D Brown, Jason S Carroll, Matthew J Sikora, George C Tseng and 2 more

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity.Cellular oncology (Dordrecht, Netherlands) · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Zheqi LiDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0003-1213-640X
Tianqin LiSchool of Computer Science, Carnegie Mellon University, Pittsburgh, Pennsylvania.ORCID 0000-0003-2567-8283
Megan E YatesWomen's Cancer Research Center, Magee Women's Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-5932-1592
Yang WuWomen's Cancer Research Center, Magee Women's Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-0432-5035
Amanda FerberWomen's Cancer Research Center, Magee Women's Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-6541-5309
Lyuqin ChenDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-0173-268X
Daniel D BrownWomen's Cancer Research Center, Magee Women's Research Institute, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-7410-9514
Jason S CarrollCancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-3643-0080
Matthew J SikoraDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0003-2915-7442
George C TsengDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-5447-1014
Steffi OesterreichDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-2537-6923
Adrian V LeeDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0001-9917-514X
University of Pittsburgh · USMagee-Womens Research Institute · USCancer Research UK Cambridge Center · GBCarnegie Mellon University · USUniversity of Colorado Anschutz Medical Campus · US

Funding

Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancerR01CA256161 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, ADRIAN V, OESTERREICH, STEFFI · 2021 to 2025
$2.8M
Mechanism-based strategies to target ER-mutant endocrine resistant breast cancerR01CA221303 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI OESTERREICH, STEFFI · 2018 to 2022
$2.0M
MDC1: central regulator of estrogen receptor function and therapy response in lobular carcinomaR01CA251621 · NCI · UNIVERSITY OF COLORADO DENVER · PI SIKORA, MATTHEW J · 2022 to 2025
$1.8M
High-Throughput Computing for Genomics and Bioinformatics ResearchS10OD028483 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, ADRIAN V · 2021 to 2021
$574k
Functional Characterization and Clinical Prevalence of ESR1 Fusions in Advanced Endocrine Resistant Breast CancerF30CA250167 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YATES, MEGAN · 2020 to 2024
$249k
Cancer Research UK 20411NCI NIH HHS F30 CA250167NCI NIH HHS R01 CA221303NCI NIH HHS R01 CA251621NCI NIH HHS R01 CA256161NIH HHS S10 OD028483
6 · The paper itself

Abstract

As one of the most successful cancer therapeutic targets, estrogen receptor-α (ER/ESR1) has been extensively studied over the past few decades. Sequencing technological advances have enabled genome-wide analysis of ER action. However, comparison of individual studies is limited by different experimental designs, and few meta-analyses are available. Here, we established the EstroGene database through unified processing of data from 246 experiments including 136 transcriptomic, cistromic, and epigenetic datasets focusing on estradiol (E2)-triggered ER activation across 19 breast cancer cell lines. A user-friendly browser (https://estrogene.org/) was generated for multiomic data visualization involving gene inquiry under user-defined experimental conditions and statistical thresholds. Notably, annotation of metadata associated with public datasets revealed a considerable lack of experimental details. Comparison of independent RNA-seq or ER ChIP-seq data with the same design showed large variability and only strong effects could be consistently detected. Temporal estrogen response metasignatures were defined, and the association of E2 response rate with temporal transcriptional factors, chromatin accessibility, and heterogeneity of ER expression was evaluated. Unexpectedly, harmonizing 146 E2-induced transcriptomic datasets uncovered a subset of genes harboring bidirectional E2 regulation, which was linked to unique transcriptional factors and highly associated with immune surveillance in the clinical setting. Furthermore, the context dependent E2 response programs were characterized in MCF7 and T47D cell lines, the two most frequently used models in the EstroGene database. Collectively, the EstroGene database provides an informative and practical resource to the cancer research community to uniformly evaluate key reproducible features of ER regulomes and unravels modes of ER signaling. SIGNIFICANCE: A resource database integrating 246 publicly available ER profiling datasets facilitates meta-analyses and identifies estrogen response temporal signatures, a bidirectional program, and model-specific biases.

Indexed as

Breast NeoplasmsGene Expression Regulation, NeoplasticReceptors, EstrogenCell Line, TumorDatabases, GeneticEstradiolEstrogen Receptor alphaEstrogensFemaleHumansEstradiolEstrogen Receptor alphaEstrogensReceptors, Estrogen

Identifiers

PMID37272757
PMCPMC10527051
OpenAlexW4379376826

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.